NeoGenomics Reports Strong Q4 and Full-Year 2025 Results

Highlights include record quarterly revenue, continued clinical growth, and progress on key initiatives

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

NeoGenomics (NASDAQ:NEO), a leading provider of cancer-focused genetic and molecular testing services, reported fourth-quarter and full-year 2025 results that reflected improving execution through the year. The company reported record quarterly revenue of $190 million, up 11% year-over-year, driven by 16% growth in clinical revenue. For the full year 2025, NeoGenomics reported total revenue of $727 million, up 10% versus 2024, with clinical revenue increasing 15% and non-clinical revenue declining 24%.

Why it matters

NeoGenomics' strong financial performance and continued growth in its clinical business demonstrate the company's ability to navigate industry challenges and capitalize on the growing demand for advanced cancer diagnostics. The company's strategic focus on higher-value testing and next-generation sequencing positions it well to drive long-term growth and profitability.

The details

In the fourth quarter, NeoGenomics reported that total test volumes rose 11% and average unit price (AUP) increased 5%. The company said it was intentionally reducing exposure to certain high-volume, lower-value business to shift capacity toward more therapy-guided and higher-value testing. NeoGenomics also highlighted progress on key initiatives, including the launch of five new NGS products in 2023 that contributed 22% of clinical revenue in Q4, and the planned full clinical launch of its RaDaR ST minimal residual disease (MRD) test by the end of February 2026.

  • NeoGenomics reported fourth-quarter and full-year 2025 results on February 18, 2026.
  • The company plans to launch its RaDaR ST MRD test by the end of February 2026.
  • NeoGenomics expects to add more than 25 oncology sales specialists by the third quarter of 2026 to support the MRD opportunity.

The players

NeoGenomics

A leading provider of cancer-focused genetic and molecular testing services, headquartered in Fort Myers, Florida, and operating an integrated network of laboratories across the United States, Europe, and Asia.

Tony Zook

CEO of NeoGenomics.

Abhishek Jain

EVP of Finance and incoming CFO of NeoGenomics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.